Stockholm:ALVO SDB

Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to EyleaAdvanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea

Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular…

1 month ago
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuersNotification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by…

3 months ago
Alvotechs Lenders Lower Interest on Senior Secured Term Loan FacilityAlvotechs Lenders Lower Interest on Senior Secured Term Loan Facility

Alvotechs Lenders Lower Interest on Senior Secured Term Loan Facility

REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the…

3 months ago
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 millionAlvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG…

4 months ago